Adverse events associated with high-dose ribavirin: Evidence from the Toronto outbreak of severe acute respiratory syndrome

Pharmacotherapy

Volumn 27, Issue 4, 2007, Pages 494-503

  Muller, Matthew P ^a,b   Dresser, Linda ^a   Raboud, Janet ^c   McGeer, Allison ^a   Rea, Elizabeth ^b   Richardson, Susan E ^d   Mazzulli, Tony ^a   Loeb, Mark ^e   Louie, Marie ^f  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e MCMASTER UNIVERSITY   (Canada)

^f PROVINCIAL LABORATORY FOR PUBLIC HEALTH   (Canada)

Author keywords

Adverse events; Hemolytic anemia; Ribavirin; SARS; Severe acute respiratory syndrome

Indexed keywords

CORTICOSTEROID; RIBAVIRIN;

ADULT; ANEMIA; ANTIVIRAL THERAPY; ARTICLE; BRADYCARDIA; CANADA; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENCY; FEMALE; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS; HUMAN; HYPOCALCEMIA; HYPOMAGNESEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MUSCLE SPASM; PANCREATITIS; SEVERE ACUTE RESPIRATORY SYNDROME; SIDE EFFECT; TETANY; TRANSAMINITIS;

ADRENAL CORTEX HORMONES; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANEMIA; ANTIVIRAL AGENTS; BRADYCARDIA; CANADA; COHORT STUDIES; DISEASE OUTBREAKS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MAGNESIUM DEFICIENCY; MALE; MEDICAL RECORDS SYSTEMS, COMPUTERIZED; MIDDLE AGED; RETROSPECTIVE STUDIES; RIBAVIRIN; SEVERE ACUTE RESPIRATORY SYNDROME; TETANY; TREATMENT OUTCOME;

EID: 34047229944     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.4.494     Document Type: Article

References (50)

1. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of Virazole: 1-β-D-ribofuranosyl- l,2,4-triazole-3-carboxamide. Science 1972;177:705-6.
2. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004;39:1147-71.
3. American Academy of Pediatrics Committee on Infectious Diseases. Use of ribavirin in the treatment of respiratory syncytial virus infection. Pediatrics 1993;92:501-4.
4. McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med 1986;314:20-6.
5. Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled clinical trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis 1991;164:1119-27.
6. Kilgore PE, Ksiazek TG, Rollin PE, et al. Treatment of Bolivian hemorrhagic fever with intravenous ribavirin. Clin Infect Dis 1997;24:718-22.
7. Enria DA, Maiztegui JI. Antiviral treatment of Argentine hemorrhagic fever. Antiviral Res 1994;23:23-31.
8. Borio L, Inglesby T, Peters CJ, et al. Hemorrhagic fever viruses as biological weapons: medical and public health management. JAMA 2002;287:2391-405.
9. Huggins JW. Prospects for treatment of viral hemorrhagic fevers with ribavirin, a broad-spectrum antiviral drug. Rev Infect Dis 1989;11(supp14):S750-61.
10. Cameron CE, Castro C. The mechanism of action of ribavirin: lethal mutagenesis of RNA virus genomes mediated by the viral RNA-dependent RNA polymerase. Curr Opin Infect Dis 2001;14:757-64.
11. Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003;348:1986-94.
12. Poutanen SM, Low DE, Henry B, et al. Identification of severe acute respiratory syndrome in Canada. N Engl J Med 2003;348:1995-2005.
13. Chen F, Chan KH, Jiang Y, et al. In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J Clin Virol 2004;31:69-75.
14. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003;361:2045-6.
15. Stroher U, DiCaro A, Li Y, et al. Severe acute respiratory syndrome-related coronavirus is inhibited by interferon-α. J Infect Dis 2004;189:1164-7.
16. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004;59:252-6.
17. Booth CM, Matukas LM, Tomlinson GA, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA 2003;289:2801-9.
18. Zhao Z, Zhang F, Xu M, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003;52(pt 8):715-20.
19. Tsui PT, Kwok ML, Yuen H, Lai ST. Severe acute respiratory syndrome: clinical outcome and prognostic correlates. Emerg Infect Dis 2003;9:1064-9.
20. Leong HN, Ang B, Earnest A, Teoh C, Xu W, Leo YS. Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003. Trop Med Int Health 2004;9:923-7.
21. Avendano M, Derkach P, Swan S. Clinical course and management of SARS in health care workers in Toronto: a case series. Can Med Assoc J 2003;168:1649-60.
22. Knowles SR, Phillips EJ, Dresser L, Matukas L. Common adverse events associated with the use of ribavirin for severe acute respiratory syndrome in Canada. Clin Infect Dis 2003;37:1139-42.
23. Koren G, King S, Knowles S, Phillips E. Ribavirin in the treatment of SARS: a new trick for an old drug? Can Med Assoc J 2003;168:1289-92.
24. Svoboda T, Henry B, Shulman L, et al. Public health measures to control the spread of the severe acute respiratory syndrome during the outbreak in Toronto. N Engl J Med 2004;350:2352-61.
25. Tang P, Louie M, Richardson SE, et al. Interpretation of diagnostic laboratory tests for severe acute respiratory syndrome: the Toronto experience. Can Med Assoc J 2004;170:47-54.
26. Muller MP, Richarden SE, McGeer A, et al. Early diagnosis of SARS: lessons from the Toronto SARS outbreak. Eur J Clin Microbiol Infect Dis 2006 ;25:230-7.
27. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1623-32.
28. Brok J, Gluud LL, Gluud C. Ribavirin monotherapy for chronic hepatitis C infection: a Cochrane hepato-biliary group systematic review and meta-analysis of randomized trials. Am J Gastroenterol 2006;101:842-7.
29. McEvoy GK, Miller J, Litvak K, eds. AHFS drug information, 2005. Bethesda, MD: American Society of Health-System Pharmacists, 2005.
30. Pockros PJ, Reindollar R, McHutchinson J, et al. The safety and tolerability of daily infergen plus ribavirin in the treatment of naive chronic hepatitis C patients. J Viral Hepat 2003;10:55-60.
31. Forni AL, Schluger NW, Roberts RB. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis 1994;19:454-62.
32. Chapman LE, Mertz GJ, Peters CJ, et al, for the Ribavirin Study Group. Intravenous ribavirin for hantavirus pulmonary syndrome: safety and tolerance during 1 year of open-label experience. Antivir Ther 1999;4:211-19.
33. Tsang K, Zhong NS. SARS: pharmacotherapy Respirology 2003;8(suppl):S25-30.
34. Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med 2003;139:715-23.
35. Wang JT, Sheng WH, Fang CT, et al. Clinical manifestations, laboratory findings, and treatment outcomes of SARS patients. Emerg Infect Dis 2004;10:818-24.
36. Chan KS, Zheng JP, Mok YW, et al. SARS: prognosis, outcome and sequelae. Respirology 2003;8(suppl):S36-40.
37. Zou Z, Yang Y, Chen J, et al. Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect Dis 2004;38:483-9.
38. Ko SF, Lee TY, Huang CC, et al. Severe acute respiratory syndrome: prognostic implications of chest radiographie findings in 52 patients. Radiology 2004;233:173-81.
39. Chau TN, Lee PO, Choi KW, et al. Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome. Am J Med 2004;117:249-54.
40. Harrell FE. Regression modeling strategies. New York: Springer, 2001.
41. Schafer JL. Multiple imputation: a primer. Stat Methods Med Res 1999;8:3-15.
42. Ellenberg JH. Selection bias in observational and experimental studies. Stat Med 1994;13:557-67.
43. Bland JM, Altman DG. Multiple significance tests: the Bonferroni method [statistics notes]. BMJ 1995;310:170.
44. Chiou HE, Liu CL, Buttrey MJ, et al. Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers. Chest 2005;128:263-72.
45. So LK, Lau AC, Yam LY, et al. Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003;361:1615-17.
46. Peiris JS, Chu CM, Cheng VC, et al. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003;361:1767-72.
47. Liu CY, Huang LJ, Lai CH, et al. Clinical characteristics, management and prognostic factors in patients with probable severe acute respiratory syndrome (SARS) in a SARS center in Taiwan. J Chin Med Assoc 2005;68:110-17.
48. Zaloga GP, Chernow B. The multifactorial basis for hypocalcemia during sepsis: studies of the parathyroid hormone-vitamin D axis. Ann Intern Med 1987;107:36-41.
49. Zivin JR, Gooley T, Zager RA, Ryan MJ. Hypocalcemia: a pervasive metabolic abnormality in the critically ill. Am J Kidney Dis 2001;37:689-98.
50. Chau TN, Lee KC, Yao H, et al. SARS-associated viral hepatitis caused by a novel coronavirus: report of three cases. Hepatology 2004;39:302-10.